Dr. Jeremie Calais
Claim this profileUCLA / Jonsson Comprehensive Cancer Center
Expert in Prostate Cancer
Studies Cancer
15 reported clinical trials
18 drugs studied
Area of expertise
1Prostate Cancer
Global LeaderStage IV
BRCA positive
2Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Jeremie Calais is currently running
177Lu-PSMA-617
for Prostate Cancer
This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radioactive (tracer) component being delivered by prostate-specific membrane antigen (PSMA)-617, has physical properties that make it ideal radionuclide (imaging tests that uses a small dose tracer) for treatment of metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA-617 works by binding to prostate cancer cells and inducing damage to deoxyribonucleic acid (DNA) inside prostate cancer cells. Giving 177Lu-PSMA-617 may improve treatment outcomes for patients with mCRPC.
Recruiting1 award Phase 212 criteria
99mTc-PSMA Imaging
for Prostate Cancer
This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.
Recruiting1 award Phase < 16 criteria
More about Jeremie Calais
Clinical Trial Related1 year of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jeremie Calais has experience with
- Positron Emission Tomography
- Computed Tomography
- Gallium Ga 68 FAPi-46
- Gallium Ga 68 Gozetotide
- Gallium Ga 68-labeled PSMA-11
- 177Lu-PSMA-617
Breakdown of trials Jeremie Calais has run
Prostate Cancer
Soft Tissue Sarcoma
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeremie Calais specialize in?
Jeremie Calais focuses on Prostate Cancer and Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are BRCA positive.
Is Jeremie Calais currently recruiting for clinical trials?
Yes, Jeremie Calais is currently recruiting for 5 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Jeremie Calais has studied deeply?
Yes, Jeremie Calais has studied treatments such as Positron Emission Tomography, Computed Tomography, Gallium Ga 68 FAPi-46.
What is the best way to schedule an appointment with Jeremie Calais?
Apply for one of the trials that Jeremie Calais is conducting.
What is the office address of Jeremie Calais?
The office of Jeremie Calais is located at: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California 90095 United States. This is the address for their practice at the UCLA / Jonsson Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.